Pricing Log in Create free account
Saturday 17 October 2026 Export IMNN’s income statement to Excel — free account

Imunon, Inc.

IMNN Healthcare Biotechnology

Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00. In the quarter to June 2026, EPS grew 71.1% and free cash flow fell 4.24%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.02 0.04 −3.77%
Market cap
$6.0M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
2/9
Altman Z
−12.47
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.04
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — 1 2 3 — —
Insider Ownership 7.50%

Capital & Financial Ratios $m

Market Cap 5.95
Revenue 0.50
Net Income (14.71)
Free Cash Flow (15.20)
Net Debt (1.33)
Current Ratio 1.82 (at or above 1.5: strong)
Debt/Equity 1.32
P/E ratio 0.00
Fwd P/E (0.51) (negative: loss-making)
P/S ratio 10.67 (above 10: high)
P/B ratio 2.76
Past 5Y EPS Growth —
This Y EPS Growth 65.42% (at or above 15%: strong)
Next Y EPS Growth 22.95% (at or above 15%: strong)
Next Y revenue growth (66.00%) (below 0%: weak)
Next 5Y EPS Growth 41.53% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 8.0×, against a ten-year median of 16.8×; over the ten years it ranged from −46.6× in 2022 to 183× in 2020.
P/S against its own 10 years 1.70%
10-year low 10-year high
P/B against its own 10 years 78.84%
10-year low 10-year high
EV/Sales against its own 10 years 9.48%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 16 6 9 7
Receivables — — — —
Inventory — — — —
Other 3 2 2 2
18 8 11 9
2023 2024 2025 Q'26
Payables 4 1 1 2
ST’ Debt — — — —
Other — — — —
7 5 5 5

Compound Annual Growth %

10y 5y 3y
Sales (12.94%) 0.00% 0.00%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (10.06%) (17.62%) (37.79%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’22 0 0 0 0 1
’21 0 0 0 0 1
’20 0 0 0 0 1
’19 0 0 0 0 1
’18 0 0 0 0 1
’17 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (3) — — —
’25 (3) (3) (4) (4) (14)
’24 (6) (5) (4) (4) (19)
’23 (4) (7) (4) (4) (19)
’22 (8) (5) (5) (5) (23)
’21 (5) (3) (4) (5) (16)
’20 (5) (3) (4) (4) (16)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (3) — — —
’25 (3) (3) (4) (4) (14)
’24 (6) (5) (4) (4) (19)
’23 (4) (7) (5) (4) (19)
’22 (8) (6) (5) (5) (23)
’21 (5) (3) (4) (5) (17)
’20 (5) (3) (4) (4) (16)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.84) (0.54) — — —
’25 (3.65) (1.87) (1.16) (1.29) (6.83)
’24 (6.78) (6.65) (4.43) (3.00) (21.12)
’23 (8.87) (7.95) (4.82) (6.78) (28.16)
’22 (23.73) (11.34) (11.34) (20.99) (65.58)
’21 (43.11) (11.73) (11.73) 17.84 (49.93)
’20 (39.09) (35.18) (46.91) (9.77) (130.96)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 794.35 242.61 264.13 205.43 84.13 105.65 16.43 8.22 6.26 2.99

Analyst estimates 2026–2028

Powerpack
High 5,450.87 1,725.65 680.87 514.57 1,271.74 680.87 121.30 22.43 47.61 41.22
People
People Employees 19 21 29 29 27 29 31 33 25 20
Revenue/emp, $m 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.00 0.00 0.00
Income, $m
Income, $m Revenue 1 1 1 1 1 1 1 — — —
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 — — —
EBT (22) (20) (22) (19) (23) (22) (37) (21) (19) (14)
EBT margin, % (4,410.74) (4,080.44) (4,460.50) (3,733.60) (4,665.88) (4,430.54) (7,493.06) 0.00 0.00 0.00
Net income (22) (20) (12) (17) (21) (21) (36) (20) (19) (14)
Depreciation 1 1 1 1 1 1 1 1 1 1
Per share, $
Per share, $ Revenue 52.63 12.82 5.56 4.48 3.06 1.20 0.91 0.00 0.00 0.00
Earnings (2,326.86) (531.64) (132.91) (150.50) (130.96) (49.93) (65.58) (28.16) (21.12) (6.83)
Cash flow (1,934.67) (426.72) (78.24) (181.37) (95.59) (38.97) (42.16) (27.42) (17.16) (6.54)
Capex (6.58) (0.99) (1.54) (3.13) (0.12) (0.75) (0.49) (0.65) (0.03) (0.13)
Free cash flow (1,941.25) (427.71) (79.78) (184.50) (95.70) (39.72) (42.64) (28.07) (17.18) (6.68)
Book value 707.98 684.73 231.79 130.34 113.90 134.03 53.53 19.30 3.86 3.33
Shares, m 0 0 0 0 0 0 1 1 1 2
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — — —
P/S 16.65 43.04 49.66 74.74 45.40 87.96 21.44 — — —
P/B 1.24 0.81 1.19 2.57 1.22 0.79 0.37 — — —
EV/Sales 10.68 (2.66) 13.27 60.95 18.94 0.89 (37.83) — — —
EV/FCF (0.29) 0.08 (0.92) (1.48) (0.61) (0.03) 0.81 — — —
Cash, $m
Cash, $m Operating cash flow (18) (17) (7) (20) (16) (16) (23) (19) (19) (14)
Capex 0 0 0 0 0 0 0 0 0 0
Free cash flow (18) (17) (7) (21) (16) (17) (23) (19) (19) (14)
Balance, $m
Balance, $m Working capital (4) 18 22 8 12 45 27 11 3 6
Total debt 3 — 9 8 4 6 5 — — —
Net debt (4) (24) (18) (7) (13) (44) (30) (16) (6) (9)
Shareholders’ equity 7 27 21 15 19 56 29 13 4 7
Returns, %
Returns, % ROA (55.22) (52.95) (25.18) (39.59) (56.68) (37.23) (60.83) (59.23) (117.72) (131.74)
ROIC (532.96) (455.08) (493.72) (167.77) (214.70) (107.08) 0.00 0.00 0.00 0.00
ROE (162.69) (124.13) (49.97) (95.15) (129.54) (55.83) (84.34) (91.37) (211.21) (256.41)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Dec 2022

Charts ten years each

Imunon, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EVGN Evogene Ltd. $6.3M — (loss-making) — (loss-making) −35.02% (below 0%: shrinking) n/m +17.72% (above 0%: growing) 40.63% (738.62%) Compare
LEXX Lexaria Bioscience Corp. $6.3M — (loss-making) — (loss-making) −89.12% (below 0%: shrinking) n/m +53.90% (above 0%: growing) 100.00% 0.00% Compare
ENVB Enveric Biosciences, Inc. $6.2M — (loss-making) — (loss-making) −7.28% (below 0%: shrinking) n/m −29.34% (below 0%: shrinking) 0.00% 0.00% Compare
TRAW Traws Pharma, Inc. $6.2M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −25.51% (below 0%: shrinking) 0.00% 0.00% Compare
ALZN Alzamend Neuro, Inc. $6.2M — (loss-making) — — n/m +51.82% (above 0%: growing) 0.00% 0.00% Compare
NRSN NeuroSense Therapeutics Ltd. $6.0M — (loss-making) — — n/m −23,458.82% (below 0%: shrinking) — 0.00% Compare
IMNN Imunon, Inc. $6.0M — (loss-making) — (loss-making) 0.00% n/m −4.24% (below 0%: shrinking) 0.00% 0.00%
ORGS Orgenesis Inc. $5.7M — (loss-making) 1.0× +82.42% (above 0%: growing) n/m −317.93% (below 0%: shrinking) 2,780.73% (6,044.52%) Compare
CANF Can-Fite Biopharma Ltd $5.6M — (loss-making) — (loss-making) −1.18% (below 0%: shrinking) n/m +12.63% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $6.2M — — −21.15% — −6.44% 0.00% 0.00%

All 614 Biotechnology stocks →

Imunon, Inc. (IMNN) key facts

  • Imunon, Inc. (IMNN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00.
  • As of October 16, 2026, IMNN traded at $1.02, a market capitalization of $6.0 million.
  • Return on equity was −256.4% and debt-to-equity 1.32.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −12.47 (distress zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.

Imunon, Inc. (IMNN) Latest News

25 Mar

Impact 5 ·
stockrow.com/IMNN · Data as of Dec 31, 2022 · For information only; not investment advice. · © 2026 stockrow.com